ArticleJAMA oncology2018
Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years.
Article in JAMA oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Characteristics and innovative points of clinical trials of radiotherapy combined with immune checkpoint inhibitors in NSCLC over the past decade.Frontiers in medicine · 2025Pooled it
- Evaluation of Italian radiotherapy research from 1985 to 2005: preliminary analysis.La Radiologia medica · 2019Pooled it
- Causal machine learning for extracting insights from observational radiotherapy data.NPJ digital medicine · 2026Article
- A review of clinical trial radiotherapy quality assurance: value, evolution and lessons.Clinical and translational radiation oncology · 2026Review
- Fatigue, physical and daily activity, and self-perceived work ability in cancer survivors: a long-term follow-up study with a matched non-cancer reference group.Journal of cancer survivorship : research and practice · 2026Article
- National Institutes of Health Funding to Support Radiation Oncology Research: A Comparative Trend Analysis Over a Decade, 2011-2021.Advances in radiation oncology · 2025Article
- The impact of Clinical Trials Radiographers on set-up and recruitment to radiotherapy trials.Technical innovations & patient support in radiation oncology · 2025Article
- Integrating Audiovisual Immersion Into Pediatric Radiation Therapy Across Multiple Centers: Methodology, Timeliness, and Cost of the Audiovisual-Assisted Therapeutic Ambience in Radiation Therapy Prospective Multi-Institutional Trial.Advances in radiation oncology · 2024Article
- Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023.British journal of clinical pharmacology · 2024Article
- Characteristics of Out-of-Hospital Cardiac Arrest Trials Registered in ClinicalTrials.gov.Journal of clinical medicine · 2024Article
- Survey of research attitudes of RTTs working in Scotland: A Scottish radiographer research forum collaboration.Technical innovations & patient support in radiation oncology · 2024Article
- BRD7 enhances the radiosensitivity of nasopharyngeal carcinoma cells by negatively regulating USP5/METTL3 axis-mediated homologous recombination repair.International journal of biological sciences · 2024Article
- Article
- The characteristics of oncological clinical trials investigating the synergistic effect of radiotherapy and immune checkpoint inhibitors: a cross-sectional study.Translational cancer research · 2023Article
- The landscape of investigator-initiated oncology trials conducted in mainland China during the past decade (2010-2019).Cancer innovation · 2023Review
- Characteristics of immunotherapy trials for nasopharyngeal carcinoma over a 15-year period.Frontiers in immunology · 2023Article
- Trends and variation in data quality and availability on the European Union Clinical Trials Register: A cross-sectional study.Clinical trials (London, England) · 2022Article
- Characteristics and trends of globally registered glioma clinical trials in the past 16 years.Therapeutic advances in neurological disorders · 2022Article
- Ultrasound-Stimulated Microbubbles Inhibit Aggressive Phenotypes and Promotes Radiosensitivity of esophageal squamous cell carcinoma.Bioengineered · 2021Article
- Characteristics of stereotactic radiotherapy clinical trials registered on ClinicalTrials.gov.Translational cancer research · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Modern precision radiotherapy is an innovative and effective treatment of cancer, yet it is unclear how radiotherapy trials are affected by expanding targeted and immune therapies and declining National Institutes of Health funding. Objective: To analyze and compare the characteristics of radiotherapy trials with other oncological trials registered on ClinicalTrials.gov. Design, Setting, and Participants: This is a cross-sectional analysis of trials registered on ClinicalTrials.gov between June 1, 2007, and May 8, 2017. Records of all 243 758 clinical studies registered by May 8, 2017, were downloaded, but only 25 907 interventional oncological trials registered between June 1, 2007, and May 8, 2017, and whose primary purpose was "treatment" were included in the final analysis. Trials were categorized according to cancer type and other registration information. Main Outcomes and Measures: Characteristics of radiotherapy trials were compared with characteristics of other oncological trials. Chronological shifts in radiotherapy trials were also analyzed. Results: Of the 25 907 trials selected, 1378 (5.3%) were radiotherapy trials and 24 529 (94.7%) were other oncological studies. The number of radiotherapy trials increased gradually from 94 (June 1, 2007, through May 31, 2008) to 192 (June 1, 2015, through May 31, 2016). Radiotherapy trials were less likely than other oncological studies to be registered before participant enrollment (763 of 1370 [55.7%] vs 16 105 of 24 434 [65.9%]; P < .001), to be blinded (45 of 1378 [3.3%] vs 2784 of 24 529 [11.3%]; P < .001), or to involve multiple geographic regions (2.4% vs 9.5%; P < .001), but they were more likely to be phase 2 to 3 (773 of 1124 [68.8%] vs 12 910 of 22 300 [57.9%]; P < .001) and to have a data-monitoring committee (839 of 1264 [66.4%] vs 11 728 of 21 060 [55.7%]; P < .001). Only a minority of radiotherapy trials were industry sponsored, which was significantly lower than for other oncological trials (80 of 1378 [5.8%] vs 10 651 of 24 529 [43.4%]; P < .001; adjusted odds ratio, 0.08; 95% CI, 0.06-0.10). The number of National Institutes of Health-sponsored radiotherapy trials decreased from 80 of 544 trials (14.7%) from 2007 to 2012 to 72 of 834 trials (8.6%) from 2012 to 2017 (P < .001). Radiotherapy trials with a sample size of more than 100 patients decreased from 155 of 543 trials (28.5%) from 2007 to 2012 to 157 of 833 trials (18.8%) from 2012 to 2017 (P < .001). Conclusions and Relevance: The limited number of and the scarcity of funding for radiotherapy trials is concerning given the integral role of radiotherapy in the clinical management of patients with cancer worldwide. A multidisciplinary collaboration to promote and fund more radiotherapy research is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.